Evidence map›Paper›PMID 36737630›Full record

ArticleScientific reports2023

Plasmodium falciparum infection prevalence among children aged 6-59 months from independent DHS and HIV surveys: Nigeria, 2018.

Adan Oviedo, Ado Abubakar, Perpetua Uhomoibhi, Mark Maire, Uwem Inyang, Bala Audu, Nnaemeka C Iriemenam, Abiodun Ogunniyi, James Ssekitooleko, Jo-Angeline Kalambo and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Adan OviedoMalaria Branch, Division of Parasitic Diseases and Malaria, United States Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA.
Ado AbubakarInstitute of Human Virology Nigeria, Abuja, Nigeria.
Perpetua UhomoibhiNational Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria.
Mark MaireUS President's Malaria Initiative, Abuja, Nigeria.
Uwem InyangUnited States Agency for International Development, Abuja, Nigeria.
Bala AuduNational Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria.
Nnaemeka C IriemenamDivision of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.
Abiodun OgunniyiNigeria Centre for Disease Control, Abuja, Nigeria.
James SsekitoolekoThe Global Fund to Fight AIDS, Tuberculosis, and Malaria, Geneva, Switzerland.
Jo-Angeline KalamboThe Global Fund to Fight AIDS, Tuberculosis, and Malaria, Geneva, Switzerland.
Stacie M GrebyDivision of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.
Nwando MbaNigeria Centre for Disease Control, Abuja, Nigeria.
Mahesh SwaminathanDivision of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.
Chikwe IhekweazuNigeria Centre for Disease Control, Abuja, Nigeria.
McPaul I OkoyeDivision of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.
Eric Rogier *Malaria Branch, Division of Parasitic Diseases and Malaria, United States Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA.
Laura C Steinhardt *Malaria Branch, Division of Parasitic Diseases and Malaria, United States Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA. iyp6@cdc.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prevalence estimates are critical for malaria programming efforts but generating these from non-malaria surveys is not standard practice. Malaria prevalence estimates for 6-59-month-old Nigerian children were compared between two national household surveys performed simultaneously in 2018: a Demographic and Health Survey (DHS) and the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). DHS tested via microscopy (n = 8298) and HRP2-based rapid diagnostic test (RDT, n = 11,351), and NAIIS collected dried blood spots (DBS) which were later tested for histidine-rich protein 2 (HRP2) antigen (n = 8029). National Plasmodium falciparum prevalence was 22.6% (95% CI 21.2- 24.1%) via microscopy and 36.2% (34.6- 37.8%) via RDT according to DHS, and HRP2 antigenemia was 38.3% (36.7-39.9%) by NAIIS DBS. Between the two surveys, significant rank-order correlation occurred for state-level malaria prevalence for RDT (Rho = 0.80, p < 0.001) and microscopy (Rho = 0.75, p < 0.001) versus HRP2. RDT versus HRP2 positivity showed 24 states (64.9%) with overlapping 95% confidence intervals from the two independent surveys. P. falciparum prevalence estimates among 6-59-month-olds in Nigeria were highly concordant from two simultaneous, independently conducted household surveys, regardless of malaria test utilized. This provides evidence for the value of post-hoc laboratory HRP2 detection to leverage non-malaria surveys with similar sampling designs to obtain accurate P. falciparum estimates.

Indexed as

Acquired Immunodeficiency SyndromeMalaria, FalciparumAntigens, ProtozoanChildChild, PreschoolDiagnostic Tests, RoutineHealth SurveysHumansInfantNigeriaPlasmodium falciparumPrevalenceProteinsProtozoan ProteinsSensitivity and SpecificityAntigens, ProtozoanProteinsProtozoan Proteins

Identifiers

PMID36737630
PMCPMC9898257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.